Año 2025 / Volumen 117 / Número 8
Original
Prevalence and evolution of newly diagnosed autoimmune gastritis in a large Spanish retrospective cohort

441-446

DOI: 10.17235/reed.2025.11101/2025

Esteban Fuentes-Valenzuela, Sergio Escribano Cruz, Javier Parra Villanueva, Almudena Calvache Rodríguez, Ariadna Gil Díaz, María del Carmen López-Martín, Itziar Rubio de la Plaza, Santiago Blanco, Irene Chivato Martín-Falquina, Beatriz Rodríguez-Batllori Aran, Raquel Latorre Martinez, Luis Alonso Castillo Herrera, Rafael Olvera, Daniel Alcalde Rodríguez, Karina Guzmán López, Alicia Bejerano Domínguez,

Resumen
Introduction: There is growing interest in autoimmune gastritis (AIG), particularly regarding its prevalence and natural history. Methods. A retrospective observational study was performed, including all patients with positive parietal cell antibodies who underwent gastroscopy between 2013 and 2023. The first subsequent gastroscopy was defined as follow-up endoscopy and considered for histological comparison. Categorization of histological stages was as follows; stage 0 (potential), stage I (non-atrophic gastritis), stage II (atrophic gastritis) and stage III (dysplasia, neuroendocrine tumor or adenocarcinoma). Results: A total of 426 patients were included, 316 were female with a median of 54.4 years (IQR 45.3-63.2). During this period, a total of 26798 patients underwent at least one upper endoscopy, so the prevalence of AIG was 1.6% (95% CI 1.4-1.7%). Histologically, 105 patients were classified as potential AIG (24.7%), 99 patients as stage I (23,2%), 215 patients as stage II (50.5%) and 7 patients as stage III (1.6%). 153 patients had a follow-up endoscopy. A significant increase of advanced stage disease was observed at follow-up (difference 18.7% 95% CI 7.6%-29%; p=0.001) and a decrease of potential GAI (difference 20.2% 95% CI 11.8% -28.7%; p<0.001). At baseline, 39 patients exhibited hyperplastic polyps (9.2%), 8 patients fundic gland polyps (1.9%), 3 adenomas with low-grade dysplasia (0.7%) and 3 patients presented G1 neuroendocrine tumors (0.7%). Only one patient (0.2%) was diagnosed with signet-ring cell gastric carcinoma. Conclusions: AIG has a low prevalence among patients undergoing gastroscopy. Biopsies in patients with positive parietal cell antibodies showed that around half of the population exhibit significant atrophy and a notable progressive disease.
Resumen coloquial
Autoimmune gastritis is a chronic disorder caused by autoantibodies. Its evolution and prevalence in the Spanish population are not well-documented. Therefore, the aim of this study was to assess the progression observed at follow-up endoscopy and the prevalence of this condition. For this purpose, a retrospective observational study was conducted, including all patients with positive auto-antibodies and gastroscopy between 2013 and 2023. Four histological stages were considered. Four hundred and twenty-six patients were included. The estimated prevalence was 1.6%. 24.7% were classified as potential autoimmune gastritis, 23,2% as stage I, 50.5% as stage II, and 1.6% as stage III. A significant increase in advanced stages was observed at follow-up (difference 18.72%) and a decrease in potential GAI (difference -20.21%). Only one patient was diagnosed with gastric cancer at baseline. Autoimmune gastritis presents with a low prevalence among patients undergoing gastroscopy. Biopsies revealed that around half of the population exhibited significant atrophy and a notable progressive disease.
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Castellana C, Eusebi LH, Dajti E, et al. Autoimmune Atrophic Gastritis: A Clinical Review. Cancers (Basel). 2024;16(7). doi:10.3390/CANCERS16071310
2. Venerito M, Varbanova M, Röhl FW, et al. Oxyntic gastric atrophy in Helicobacter pylori gastritis is distinct from autoimmune gastritis. J Clin Pathol. 2016;69(8):677-685. doi:10.1136/JCLINPATH-2015-203405
3. Rugge M, Bricca L, Guzzinati S, et al. Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori-negative patients. Gut. 2023;72(1):30-38. doi:10.1136/GUTJNL-2022-327827
4. Lenti MV, Miceli E, Vanoli A, Klersy C, Corazza GR, Di Sabatino A. Time course and risk factors of evolution from potential to overt autoimmune gastritis. Dig Liver Dis. 2022;54(5):642-644. doi:10.1016/J.DLD.2021.10.001
5. Yu YF, Tong KK, Shangguan XL, et al. Research status and hotspots of autoimmune gastritis: A bibliometric analysis. World J Gastroenterol. 2023;29(42):5781-5799. doi:10.3748/WJG.V29.I42.5781
6. Nova-Camacho LM, De Burgos S, Ruiz Diaz I, Collins K. Comprehensive clinicopathologic features in autoimmune atrophic gastritis: Insights from a European cohort of 57 patients. Pathol Res Pract. 2024;263:155631. doi:10.1016/J.PRP.2024.155631
7. Miceli E, Lenti MV, Gentile A, et al. Long-Term Natural History of Autoimmune Gastritis: Results From a Prospective Monocentric Series. Am J Gastroenterol. 2024;119(5):837-845. doi:10.14309/AJG.0000000000002619
8. Park JY, Cornish TC, Lam-Himlin D, Shi C, Montgomery E. Gastric lesions in patients with autoimmune metaplastic atrophic gastritis (AMAG) in a tertiary care setting. Am J Surg Pathol. 2010;34(11):1591-1598. doi:10.1097/PAS.0B013E3181F623AF
9. Wolf EM, Plieschnegger W, Geppert M, et al. Changing prevalence patterns in endoscopic and histological diagnosis of gastritis? Data from a cross-sectional Central European multicentre study. Dig Liver Dis. 2014;46(5):412-418. doi:10.1016/J.DLD.2013.12.017
10. Notsu T, Adachi K, Mishiro T, et al. Prevalence of Autoimmune Gastritis in Individuals Undergoing Medical Checkups in Japan. Intern Med. 2019;58(13):1817-1823. doi:10.2169/INTERNALMEDICINE.2292-18
11. Cabrera de León A, Almeida González D, Almeida AA, et al. Factors associated with parietal cell autoantibodies in the general population. Immunol Lett. 2012;147(1-2):63-66. doi:10.1016/J.IMLET.2012.06.004
12. Massironi S, Gallo C, Lahner E, et al. Occurrence and characteristics of endoscopic gastric polyps in patients with autoimmune gastritis (AGAPE study): A multicentric cross-sectional study. Dig Liver Dis. 2025;57(1). doi:10.1016/J.DLD.2024.07.024
13. Rugge M, Bricca L, Guzzinati S, et al. Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori-negative patients. Gut. 2023;72(1):30-38. doi:10.1136/GUTJNL-2022-327827
14. Nasseri-Moghaddam S, Mousavian AH, Kasaeian A, et al. What is the Prevalence of Clinically Significant Endoscopic Findings in Subjects With Dyspepsia? Updated Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21(7):1739-1749.e2. doi:10.1016/j.cgh.2022.05.041
15. Rugge M, Savarino E, Sbaraglia M, Bricca L, Malfertheiner P. Gastritis: The clinico-pathological spectrum. Dig Liver Dis. 2021;53(10):1237-1246. doi:10.1016/J.DLD.2021.03.007
16. Rugge M, Fassan M, Pizzi M, et al. Autoimmune gastritis: Histology phenotype and OLGA staging. Aliment Pharmacol Ther. 2012;35(12):1460-1466. doi:10.1111/J.1365-2036.2012.05101.X
17. Rugge M, Genta RM, Malfertheiner P, et al. RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut. 2024;73(3):407-441. doi:10.1136/GUTJNL-2023-331164
18. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-388. doi:10.1055/a-0859-1883
19. Kamada T, Maruyama Y, Monobe Y, Haruma K. Endoscopic features and clinical importance of autoimmune gastritis. Dig Endosc. 2022;34(4):700-713. doi:10.1111/DEN.14175
20. Kamada T, Watanabe H, Furuta T, et al. Diagnostic criteria and endoscopic and histological findings of autoimmune gastritis in Japan. J Gastroenterol. 2023;58(3):185-195. doi:10.1007/S00535-022-01954-9
21. Conti L, Lenti MV, Di Sabatino A, et al. Seronegative autoimmune atrophic gastritis is more common in elderly patients. Dig Liver Dis. 2020;52(11):1310-1314. doi:10.1016/J.DLD.2020.04.015
Artículos relacionados

Carta

Síndrome carcinoide y análogos de la somatostatina

DOI: 10.17235/reed.2023.9525/2023

Imagen en Patología Digestiva

Hallazgo inusual en cirugía esofagogástrica: antracosis gástrica

DOI: 10.17235/reed.2022.8882/2022

Imagen en Patología Digestiva

Endoscopic resection of a duodenal neuroendocrine tumor

DOI: 10.17235/reed.2021.8232/2021

Imagen en Patología Digestiva

Atrofia vellosa intestinal, un reto endoscópico diagnóstico

DOI: 10.17235/reed.2021.8169/2021

Imagen en Patología Digestiva

A rare cause of extrahepatic biliary tract stricture: a neuroendocrine carcinoma

DOI: 10.17235/reed.2020.6491/2019

Carta

Tumor neuroendocrino simulando un tumor de Klatskin

DOI: 10.17235/reed.2019.6382/2019

Carta al Editor

Tumores neuroendocrinos quísticos del páncreas

DOI: 10.17235/reed.2017.5390/2017

Carta al Editor

A case of a mixed adenoneuroendocrine tumor of the colon

DOI: 10.17235/reed.2017.5008/2017

Carta al Editor

Tumores neuroendocrinos de páncreas: claves para afrontar la heterogeneidad

DOI: 10.17235/reed.2017.4997/2017

Carta al Editor

Tumores neuroendocrinos de páncreas: factores pronósticos

DOI: 10.17235/reed.2017.5109/2017

Carta al Editor

Tumores neuroendocrinos pancreáticos

DOI: 10.17235/reed.2017.4725/2016

Editorial

Tumores neuroendocrinos del páncreas: no tan raros y no tan benignos

DOI: 10.17235/reed.2016.4672/2016

Carta al Editor

Una forma poco común de presentación de ictericia obstructiva

DOI: 10.17235/reed.2017.4501/2016

Carta al Editor

Gastric neuroendocrine tumor presenting with gastrointestinal bleeding

DOI: 10.17235/reed.2015.3998/2015

Carta al Editor

Enteropatía sprue-like causada por olmesartán

DOI: 10.17235/reed.2015.3791/2015

Instrucciones para citar
Fuentes-Valenzuela E, Escribano Cruz S, Parra Villanueva J, Calvache Rodríguez A, Gil Díaz A, López-Martín M, et all. Prevalence and evolution of newly diagnosed autoimmune gastritis in a large Spanish retrospective cohort. 11101/2025


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 19 veces.
Este artículo ha sido descargado 0 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 24/01/2025

Aceptado: 08/04/2025

Prepublicado: 25/04/2025

Publicado: 24/07/2025

Tiempo de revisión del artículo: 64 días

Tiempo de prepublicación: 91 días

Tiempo de edición del artículo: 181 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2025 y Creative Commons. Revista Española de Enfermedades Digestivas